Research programme: Nanobodies - Ablynx/Novartis
Latest Information Update: 22 Jun 2018
At a glance
- Originator Ablynx
- Developer Ablynx; Novartis
- Class Anti-inflammatories; Proteins
- Mechanism of Action CXCR receptor modulators; Interleukin 8B receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 19 Jun 2018 Ablynx has been acquired by Sanofi
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in Belgium (Parenteral)
- 13 Jul 2010 Preclinical development is ongoing in Belgium